Literature DB >> 21912404

Infectious disease: childhood meningitis may be preventable if we can afford it.

Andrew J Pollard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21912404     DOI： 10.1038/nrneurol.2011.141

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  8 in total

1.  Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-01-28       Impact factor: 17.586

2.  Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.

Authors:  Jessica R Macneil; Amanda C Cohn; Elizabeth R Zell; Susanna Schmink; Elaine Miller; Thomas Clark; Nancy E Messonnier
Journal:  Pediatr Infect Dis J       Date:  2011-06       Impact factor: 2.129

3.  Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants.

Authors:  Kristina A Bryant; Gary S Marshall; Colin D Marchant; Noris Pavia-Ruiz; Terry Nolan; Stephen Rinderknecht; Mark Blatter; Emmanuel Aris; Pascal Lestrate; Dominique Boutriau; Leonard R Friedland; Jacqueline M Miller
Journal:  Pediatrics       Date:  2011-05-29       Impact factor: 7.124

4.  Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.

Authors:  Ameneh Khatami; Matthew D Snape; Tessa John; Sharon Westcar; Chaam Klinger; Llinos Rollinson; Dominique Boutriau; Narcisa Mesaros; Jacek Wysocki; Andrzej Galaj; Ly-Mee Yu; Andrew J Pollard
Journal:  Pediatr Infect Dis J       Date:  2011-03       Impact factor: 2.129

5.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Oleg O Bilukha; Nancy Rosenstein
Journal:  MMWR Recomm Rep       Date:  2005-05-27

6.  Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

Authors:  Jamie Findlow; Ray Borrow; Matthew D Snape; Tom Dawson; Ann Holland; Tessa M John; Anita Evans; Karen L Telford; Ellen Ypma; Daniela Toneatto; Philipp Oster; Elizabeth Miller; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2010-10-18       Impact factor: 9.079

Review 7.  Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.

Authors:  F Marc LaForce; Neil Ravenscroft; Mamoudou Djingarey; Simonetta Viviani
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

8.  Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.

Authors:  Matthew D Snape; Dominic F Kelly; Penny Salt; Sarah Green; Claire Snowden; Linda Diggle; Astrid Borkowski; Ly-mee Yu; E Richard Moxon; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2006-10-31       Impact factor: 9.079
  8 in total
  1 in total

Review 1.  Can we, should we, eradicate the meningococcus?

Authors:  Martin C J Maiden; Matthias Frosch
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.